Head-to-head · Cost-Efficiency Index
bmiMD vs Curex
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
bmiMD
Price-driven shoppers who want both molecules cheap and nationwide, with a real month-to-month option if they don't want to prepay a year.
Visit bmiMDCurex
People who want a low-cost first month, an oral option, and a verified pharmacy nationwide, and don't need a dose-by-dose price table before signing up.
Visit CurexThe verdict
bmiMD takes it, leading the Cost-Efficiency Index 82 to 81. Low $129/$179 month-to-month pricing on both molecules nationwide — the $99/$139 headline requires a full 12-month prepay, but a genuine no-commitment option still undercuts most of the ranking. Curex still earns a B− — People who want a low-cost first month, an oral option, and a verified pharmacy nationwide, and don't need a dose-by-dose price table before signing up.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs bmiMD.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | bmiMD | Curex |
|---|---|---|
| Cost-Efficiency Index | 82/100 | 81/100 |
| Semaglutide / mo | $129/mo (true month-to-month; $99/mo requires 12-mo prepay) | $199/mo Starting (first month $49) |
| Tirzepatide / mo | $179/mo (true month-to-month; $139/mo requires 12-mo prepay) | $199/mo Starting (first month $149) |
| Semaglutide / yr (modeled) | $1,548 | $2,388 |
| Tirzepatide / yr (modeled) | $2,148 | $2,388 |
| Coverage | All 50 states | All 50 states (California: oral tablet only, no injectable) |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #24 | #27 |
bmiMD
82/100Where the value is
- Low prices on both molecules even month-to-month — $129 semaglutide / $179 tirzepatide, with no dose-based escalation
- A genuine no-commitment month-to-month option exists alongside the cheaper prepay tiers, unlike sites that gate pricing entirely behind a term
- Nationwide all-50 access with both molecules disclosed
The tradeoffs
- The advertised $99/$139 headline requires a full 12-month prepay ($1,188/$1,668 paid upfront) — the true month-to-month rate is 29-30% higher
- Compounded only — no oral or brand option
Curex
81/100Where the value is
- Discounted first month well below the ongoing rate — $49 for semaglutide, $149 for tirzepatide
- Nationwide enrollment (all 50 states) plus an oral/sublingual route as an alternative to injections
- 365-day money-back guarantee and a full refund if never prescribed
The tradeoffs
- The '$199/mo' figure is labeled 'Starting,' not flat — no dose-by-dose price table is published, so the real cost at a higher maintenance dose is unverified
- California residents cannot get the injectable route at all — oral tablets only, despite the 'all 50 states' enrollment claim
Regulatory note: the FDA issued a warning letter to Curex in September 2025. We still list and link to Curex; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.